OPKO Health, Inc. (0KCS.L)
USD 1.63
(0.62%)
USD 1.63
(0.62%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 326.56 Million USD | 52.96% |
| 2022 | 213.5 Million USD | 13.62% |
| 2021 | 187.9 Million USD | -15.36% |
| 2020 | 222 Million USD | 5.11% |
| 2019 | 211.2 Million USD | 568.35% |
| 2018 | 31.6 Million USD | -80.0% |
| 2017 | 157.99 Million USD | 261.53% |
| 2016 | 43.7 Million USD | -11.54% |
| 2015 | 49.4 Million USD | -62.43% |
| 2014 | 131.5 Million USD | -42.26% |
| 2013 | 227.74 Million USD | 904.34% |
| 2012 | 22.67 Million USD | 158.95% |
| 2011 | 8.75 Million USD | -40.39% |
| 2010 | 14.69 Million USD | -25.29% |
| 2009 | 19.66 Million USD | 64.34% |
| 2008 | 11.96 Million USD | -15.95% |
| 2007 | 14.23 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 202 Thousand USD | 0.0% |
| 2001 | 202 Thousand USD | 61.6% |
| 2000 | 125 Thousand USD | -7.41% |
| 1999 | 135 Thousand USD | -32.5% |
| 1998 | 200 Thousand USD | 100.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 269.44 Million USD | -35.78% |
| 2024 Q1 | 419.57 Million USD | 28.48% |
| 2023 Q3 | 213.3 Million USD | -27.86% |
| 2023 Q1 | 211.3 Million USD | -1.03% |
| 2023 Q4 | 326.56 Million USD | 53.1% |
| 2023 Q2 | 295.67 Million USD | 39.93% |
| 2023 FY | 326.56 Million USD | 52.96% |
| 2022 Q1 | 279.5 Million USD | 48.75% |
| 2022 Q4 | 213.5 Million USD | -26.94% |
| 2022 FY | 213.5 Million USD | 13.62% |
| 2022 Q3 | 292.22 Million USD | 3.5% |
| 2022 Q2 | 282.35 Million USD | 1.02% |
| 2021 Q1 | 293.41 Million USD | 32.17% |
| 2021 FY | 187.9 Million USD | -15.36% |
| 2021 Q2 | 250.47 Million USD | -14.63% |
| 2021 Q4 | 187.9 Million USD | -23.09% |
| 2021 Q3 | 244.29 Million USD | -2.47% |
| 2020 Q2 | 331.06 Million USD | 4.87% |
| 2020 Q3 | 278.09 Million USD | -16.0% |
| 2020 Q4 | 222 Million USD | -20.17% |
| 2020 FY | 222 Million USD | 5.11% |
| 2020 Q1 | 315.69 Million USD | 49.48% |
| 2019 Q4 | 211.2 Million USD | -32.77% |
| 2019 Q3 | 314.16 Million USD | -3.26% |
| 2019 Q2 | 324.74 Million USD | 59.42% |
| 2019 FY | 211.2 Million USD | 568.35% |
| 2019 Q1 | 203.7 Million USD | 544.62% |
| 2018 Q3 | 208.75 Million USD | -0.48% |
| 2018 FY | 31.6 Million USD | -80.0% |
| 2018 Q4 | 31.6 Million USD | -84.86% |
| 2018 Q2 | 209.74 Million USD | 147.05% |
| 2018 Q1 | 84.9 Million USD | -46.26% |
| 2017 Q2 | 132.46 Million USD | 28.2% |
| 2017 Q1 | 103.32 Million USD | 136.45% |
| 2017 Q3 | 151.09 Million USD | 14.06% |
| 2017 FY | 157.99 Million USD | 261.53% |
| 2017 Q4 | 157.99 Million USD | 4.56% |
| 2016 Q2 | 109.07 Million USD | -27.25% |
| 2016 FY | 43.7 Million USD | -11.54% |
| 2016 Q3 | 51.5 Million USD | -52.78% |
| 2016 Q4 | 43.7 Million USD | -15.15% |
| 2016 Q1 | 149.91 Million USD | 203.48% |
| 2015 Q2 | 125.95 Million USD | 2.85% |
| 2015 Q1 | 122.46 Million USD | -6.87% |
| 2015 Q3 | 145.35 Million USD | 15.41% |
| 2015 Q4 | 49.4 Million USD | -66.01% |
| 2015 FY | 49.4 Million USD | -62.43% |
| 2014 FY | 131.5 Million USD | -42.26% |
| 2014 Q1 | 238.93 Million USD | 4.91% |
| 2014 Q2 | 133.71 Million USD | -44.04% |
| 2014 Q4 | 131.5 Million USD | 1.19% |
| 2014 Q3 | 129.95 Million USD | -2.81% |
| 2013 FY | 227.74 Million USD | 904.34% |
| 2013 Q2 | 208.93 Million USD | -5.2% |
| 2013 Q1 | 220.39 Million USD | 871.91% |
| 2013 Q3 | 226.74 Million USD | 8.52% |
| 2013 Q4 | 227.74 Million USD | 0.44% |
| 2012 Q3 | 21.36 Million USD | 46.61% |
| 2012 Q1 | 14.19 Million USD | 62.09% |
| 2012 FY | 22.67 Million USD | 158.95% |
| 2012 Q2 | 14.57 Million USD | 2.66% |
| 2012 Q4 | 22.67 Million USD | 6.15% |
| 2011 FY | 8.75 Million USD | -40.39% |
| 2011 Q4 | 8.75 Million USD | -30.21% |
| 2011 Q3 | 12.54 Million USD | -14.09% |
| 2011 Q2 | 14.6 Million USD | 0.36% |
| 2011 Q1 | 14.55 Million USD | -0.94% |
| 2010 Q3 | 8.56 Million USD | 40.16% |
| 2010 Q2 | 6.11 Million USD | -63.39% |
| 2010 Q1 | 16.69 Million USD | -15.12% |
| 2010 Q4 | 14.69 Million USD | 71.53% |
| 2010 FY | 14.69 Million USD | -25.29% |
| 2009 Q2 | 14.58 Million USD | -15.83% |
| 2009 Q3 | 14.93 Million USD | 2.46% |
| 2009 Q4 | 19.66 Million USD | 31.62% |
| 2009 FY | 19.66 Million USD | 64.34% |
| 2009 Q1 | 17.32 Million USD | 44.78% |
| 2008 Q1 | 13.7 Million USD | -3.74% |
| 2008 Q2 | 11.85 Million USD | -13.48% |
| 2008 Q4 | 11.96 Million USD | -0.13% |
| 2008 FY | 11.96 Million USD | -15.95% |
| 2008 Q3 | 11.98 Million USD | 1.05% |
| 2007 Q1 | 7.42 Million USD | 0.0% |
| 2007 Q4 | 14.23 Million USD | 29.92% |
| 2007 FY | 14.23 Million USD | 0.0% |
| 2007 Q3 | 10.95 Million USD | 46.33% |
| 2007 Q2 | 7.48 Million USD | 0.88% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q3 | 132 Thousand USD | -15.38% |
| 2003 Q1 | 179 Thousand USD | -11.39% |
| 2003 Q4 | - USD | -100.0% |
| 2003 Q2 | 156 Thousand USD | -12.85% |
| 2002 Q4 | 202 Thousand USD | -6.91% |
| 2002 FY | 202 Thousand USD | 0.0% |
| 2002 Q1 | 261 Thousand USD | 29.21% |
| 2002 Q2 | 239 Thousand USD | -8.43% |
| 2002 Q3 | 217 Thousand USD | -9.21% |
| 2001 FY | 202 Thousand USD | 61.6% |
| 2001 Q4 | 202 Thousand USD | 0.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q2 | 812 Thousand USD | -3.68% |
| 2001 Q1 | 843 Thousand USD | 574.4% |
| 2000 Q2 | 125 Thousand USD | 0.0% |
| 2000 Q3 | - USD | -100.0% |
| 2000 Q4 | 125 Thousand USD | 0.0% |
| 2000 FY | 125 Thousand USD | -7.41% |
| 2000 Q1 | 125 Thousand USD | -7.41% |
| 1999 Q2 | 200 Thousand USD | -81.82% |
| 1999 Q4 | 135 Thousand USD | 35.0% |
| 1999 FY | 135 Thousand USD | -32.5% |
| 1999 Q1 | 1.1 Million USD | 450.0% |
| 1999 Q3 | 100 Thousand USD | -50.0% |
| 1998 Q4 | 200 Thousand USD | 0.0% |
| 1998 FY | 200 Thousand USD | 100.0% |
| 1998 Q1 | - USD | -100.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q3 | - USD | -100.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q4 | 100 Thousand USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -793.814% |
| Dynavax Technologies Corporation | 256.91 Million USD | -27.11% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -686.39% |
| Perrigo Company plc | 4.07 Billion USD | 91.983% |
| Illumina, Inc. | 2.26 Billion USD | 85.563% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.065% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -32556.4% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 96.582% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 97.705% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -87.947% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 87.918% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -1109.944% |
| Waters Corporation | 2.35 Billion USD | 86.136% |
| Biogen Inc. | 7.33 Billion USD | 95.55% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -757.033% |
| Evolus, Inc. | 126.54 Million USD | -158.06% |
| Adicet Bio, Inc. | 17.7 Million USD | -1744.682% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -656.513% |
| bluebird bio, Inc. | 330.32 Million USD | 1.139% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 39.631% |
| FibroGen, Inc. | 170.45 Million USD | -91.584% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 88.06% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -1463.687% |
| Homology Medicines, Inc. | 44.05 Million USD | -641.281% |
| Geron Corporation | 85.89 Million USD | -280.172% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 86.382% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 26.625% |
| Myriad Genetics, Inc. | 145 Million USD | -125.217% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -25817.778% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -183.117% |
| Zoetis Inc. | 6.8 Billion USD | 95.2% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -7318.537% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 84.935% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 71.199% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 59.604% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -799.056% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 77.533% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -464.287% |
| Verastem, Inc. | 41.55 Million USD | -685.822% |
| Nektar Therapeutics | 230.4 Million USD | -41.737% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -75.222% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -10523.422% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 76.621% |
| Exelixis, Inc. | 189.94 Million USD | -71.926% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 23.771% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -216167.55% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | -135.941% |
| Imunon, Inc. | 1.13 Million USD | -28563.741% |
| Blueprint Medicines Corporation | 774.12 Million USD | 57.815% |
| Insmed Incorporated | 1.2 Billion USD | 72.877% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 78.218% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -473.04% |
| TG Therapeutics, Inc. | 110.79 Million USD | -194.746% |
| Incyte Corporation | 38.28 Million USD | -752.937% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 62.785% |